Incyte News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.05.14	Bristol-Myers, Incyte Establish Clinical Trial Collaboration On Immunotherapies (RTTNews)
14.05.14	AstraZeneca Says MedImmune Signs Clinical Study Collaboration With Incyte (RTTNews)
01.05.14	Incyte Q1 Loss Widens, Misses Street View - Quick Facts (RTTNews)
07.03.14	Incyte Announces Positive Top-Line Results From Phase III Study Of Ruxolitinib (RTTNews)
12.02.14	Incyte Posts Q4 Loss (RTTNews)
05.02.14	Merck Q4 Profit Down 14%, But Matches View; Sees 2014 Earnings In-line (RTTNews)
05.02.14	Merck, Amgen,Incyte And Pfizer To Collaborate On Anti-Cancer Combination Studies (RTTNews)
13.01.14	Incyte Appoints Novartis' Former Oncology Head Hervé Hoppenot As President, CEO (RTTNews)
31.10.13	Incyte Q3 Loss/Shr Narrows - Quick Facts (RTTNews)
29.10.13	INCY's Got More Proof, AKRX Hits New High, ILMN Opens Wallet, RGLS On Watch (RTTNews)
16.10.13	Dividend Announcements, Earnings Release Scheduled, and Data Presentations from Clinical Studies - Research Report on Questcor, Regeneron, NPS, Incyte, and Nektar (PR Newswire)
08.10.13	Early Briefing and Review: Arena Pharma Inc., Spectrum Pharma Inc., Incyte Corp. Ltd., and Geron Corp. (PR Newswire)
04.10.13	AMRN Faces FDA Panel On Oct.16, Isis Pockets $2Mln, NEOG Effects Stock Split (RTTNews)
03.10.13	Incyte Reports Results From INCB39110 Phase II Trial - Quick Facts (RTTNews)
27.09.13	Critical Alerts For Qihoo 360, Capital One, SunEdison, Incyte, and Tiffany Released By InvestorsObserver (PR Newswire)
29.08.13	Acquisitions, Dividends, and Positive Data - Research Report on Onyx, Johnson & Johnson, Medtronic, Lilly, and Incyte (PR Newswire)
26.08.13	Positive Clinical Trial Results, Regulatory Wins, and New Appointments - Research Report on Incyte, Edwards, ACADIA Pharmaceuticals, Alnylam, and Ironwood (PR Newswire)
22.08.13	Critical Alerts For Wells Fargo, SunEdison, Deere, Safeway, and Incyte Released By InvestorsObserver (PR Newswire)
22.08.13	Incyte Excites, ADMP Entitled To Patent, BSX Gets Two Thumbs Up, ORMP On Watch (RTTNews)
21.08.13	Pre-market Movers For Aug 21 (LOW, TGT, SPLS, AEO, INCY, QCOR, DMND) (RTTNews)
21.08.13	Biotech Companies Announce Financial Results and Receive New Patents - Research Report on Regeneron, Medivation, Incyte, Santarus, and ACADIA (PR Newswire)
21.08.13	Incyte Reports Top-line Results Of The Phase II RECAP Trial - Quick Facts (RTTNews)
09.08.13	Pharmaceutical Companies Announce Quarterly Financial Results - Research Report on Jazz, Acadia, Arena, Santarus, and Incyte (PR Newswire)
02.08.13	ATRC, RGEN See Rosy Future, VICL, INCY To Watch Out For, PCRX Down But Not Out (RTTNews)
29.07.13	Arena Pharma, Geron, Incyte, and Spectrum Pharma Under AAAResearchReports.com Microscope (PR Newswire)
29.07.13	Arena Pharma, Geron, Incyte, and Spectrum Pharma Under AAAResearchReports.com Microscope (PR Newswire)
25.07.13	Results Schedules, Management Changes, and Pending NDA Approvals - Research Report on Questcor, VIVUS, Exelixis, Incyte, and Chelsea Therapeutics (PR Newswire)
05.01.10	Incyte to Present at the 28th Annual JPMorgan Healthcare Conference (Businesswire)
05.11.09	Incyte Reports Third Quarter 2009 Financial Results and Provides Update on Drug Development Programs (Businesswire)
24.09.09	Incyte Announces Pricing of Public Offering of 18,000,000 Shares of Common Stock (Businesswire)
21.04.09	Incyte to Report First Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on May 7 (Businesswire)
06.12.08	Incyte's Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates Rapid and Durable Clinical Benefits in Myelofibrosis Patients (Businesswire)
06.11.08	Incyte Reports Progress in Multiple Clinical Programs Announces Third Quarter Financial Results (Businesswire)
11.06.08	Incyte to Host EULAR Webcast and Conference Call on June 12 (Businesswire)
14.02.08	Incyte Reports Progress in Multiple Clinical Programs; Expands JAK Inhibitor Program; Announces 2007 Financial Results and Provides 2008 Financial Guidance (Businesswire)
24.07.07	Phase IIa Study Results Demonstrate that Once-Daily 200 mg Dosing of INCB9471 Provided Potent and Prolonged Antiviral Activity in HIV-Infected Patients (Businesswire)
04.05.05	Incyte Announces First Quarter 2005 Results; Progress Achieved in Top (Businesswire)
24.03.05	Incyte to Present at Lehman and BioCentury Conferences (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

04.12.24		Gewinne in New York: S&P 500 legt mittags zu
19.11.24		Börse New York in Grün: S&P 500 zum Ende des Dienstagshandels im Aufwind
19.11.24		Optimismus in New York: Anleger lassen S&P 500 am Dienstagnachmittag steigen
19.11.24		Dienstagshandel in New York: S&P 500 mittags mit grünem Vorzeichen
19.11.24		Verluste in New York: S&P 500 startet im Minus
29.10.24		Börse New York in Grün: S&P 500 beendet die Sitzung im Plus
29.10.24		Börse New York: S&P 500 fester
29.10.24		Optimismus in New York: So bewegt sich der S&P 500 am Mittag

04.12.24

Gewinne in New York: S&P 500 legt mittags zu

19.11.24

Börse New York in Grün: S&P 500 zum Ende des Dienstagshandels im Aufwind

19.11.24

Optimismus in New York: Anleger lassen S&P 500 am Dienstagnachmittag steigen

19.11.24

Dienstagshandel in New York: S&P 500 mittags mit grünem Vorzeichen

19.11.24

Verluste in New York: S&P 500 startet im Minus

29.10.24

Börse New York in Grün: S&P 500 beendet die Sitzung im Plus

29.10.24

Börse New York: S&P 500 fester

29.10.24

Optimismus in New York: So bewegt sich der S&P 500 am Mittag

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Lonza Grp	550.00	5.28 %	K V
CieFinRichemont	135.70	1.53 %	K V
UBS Group	28.63	1.17 %	K V
Holcim	90.24	1.14 %	K V
Novartis	88.20	0.30 %	K V
Part Grp Hldg	1’294.00	-0.23 %	K V
Roche Hldg G	255.30	-0.23 %	K V
Sika	231.10	-0.39 %	K V
Swiss Life Hldg	687.20	-0.66 %	K V
Kuehne+Nagel Int	204.20	-3.18 %	K V

Nachrichten zu Incyte Corp.

Aktien Top/Flop

Incyte Peer Group Nachrichten

Meistgelesene Nachrichten